Backed by a 3.4 million euro EIC Pathfinder Open grant, BoneOscopy unites 6 partners across 5 countries with a shared vision: to revolutionise the treatment of bone metastasis. This ambitious project brings together world-leading expertise in particle therapy, spectroscopy, and clinical innovation.
Within the consortium, LIP – Laboratory of Instrumentation and Experimental Particle Physics plays a key role in the development of trigger detectors and fast front-end electronics essential for BoneOscopy's real-time monitoring approach. Drawing on its expertise in particle detection, electronics, and simulation, LIP contributes to all work packages, ensuring the translation of advanced instrumentation into practical clinical tools.
Together, the BoneOscopy consortium aims to establish a new standard of care for metastatic bone cancer, introducing real-time, non-invasive tumour monitoring to personalise and improve patient outcomes.
BoneOscopy aims to revolutionise bone metastasis analysis during particle beam treatments
Bone metastasis presents a significant health challenge, often inadequately addressed by traditional imaging methods. BoneOscopy aims to bridge this gap by enabling daily monitoring of tumors during treatment. Utilising spectroscopy analysis, BoneOscopy assesses bone density and calcium content without additional radiation exposure, delivering personalised and precise data that support informed treatment decisions. This innovative approach holds the potential to revolutionise metastatic bone cancer treatment, introducing a new era of precision and personalisation in therapy.
2-3 million deaths worldwide
Newly diagnosed patients will eventually develop bone metastasis
Survival rates
10-50% patients
<10% patients
Want to know more? Visit the project page: